“You have unsuccessfully attempted similar corrective actions in the past” — when your CAPA history becomes the finding
483 response filed 4 November 2025 · Citations 21 CFR 211.192, 211.42(c), 211.67(b)
A firm responded to its Form 483 by listing the corrective actions it had already put in place. That list was meant to demonstrate diligence. FDA read it as the evidence against them.
Issue 01 examined a response that blamed an individual operator. This one is what that failure mode looks like after two years of repetition — and it carries a harder lesson. Citing your prior CAPA is only a defence if the prior CAPA worked.
What FDA found
The firm manufactures a drug product in Waukegan, Illinois. Between June 2023 and August 2025, it isolated objectionable microorganisms — including Bacillus cereus — from finished drug product samples on approximately nine occasions. Since January 2025, it recovered B. cereus in at least five additional samples from the manufacturing environment.
The sequence is what matters here.
- June 2023
- First of roughly nine B. cereus isolations from finished product begins. Multiple investigations identify a root cause.
- January 2025
- The contamination issue is cited on a Form FDA 483.
- May 2025
- The issue is discussed directly with the firm at a regulatory meeting.
- October 2025
- FDA re-inspects. The same contamination problem is still present.
- May 2026
- Warning letter issued.
Two findings compounded it. First, operators were observed using cleaning tools without suitable gloves and then repeatedly touching product contact surfaces — and the firm’s own investigations had already identified objectionable aseptic behaviours as a root cause of the contamination. Second, numerous deviation investigations had noted operator failures to properly clean and disinfect equipment and valves, with those same items identified as a root cause since 2023.
FDA also noted similar CGMP observations at another site in the company’s network, in Hartland, Wisconsin.
What the firm said
The response was cooperative and substantive. The firm acknowledged “that the FDA inspection identified gaps in adherence to the corrective actions and cGMP’s.” It suspended production of the affected drug product in October 2025. It committed to verifying corrective actions and their effectiveness before notifying FDA of any intent to resume.
It then referred to several previously initiated CAPA — management controls, deviation investigations, facility and process improvements, corrections to cleanroom behaviours, cleaning and maintenance procedures, contamination controls, and retraining.
On its face this is a strong response. Voluntary shutdown, effectiveness verification before restart, and a documented history of remediation. It still failed.
Why FDA rejected it
The CAPA list was never explained
FDA’s central objection is a single sentence, and it is the one worth memorising: the response was inadequate “because you have not explained why your previous CAPA attempts were not successful.” The firm submitted a list of prior actions without a diagnosis of why any of them failed.
“Your proposed corrections are insufficient to remediate flawed facility and process design. You have unsuccessfully attempted similar corrective actions in the past.” FDA, Warning Letter 320-26-82
Behavioural fixes for a design problem
Retraining, cleanroom behaviour corrections, and revised cleaning procedures all treat the operator as the variable. FDA’s position is that the facility and process design were flawed — and that no amount of behavioural correction remediates a design that requires people to behave perfectly in order to be safe.
Testing was offered as evidence of control
The firm stated it had not released any batches with failing microbiological results. FDA rejected that reasoning outright: finished product microbiological testing “cannot be relied upon as sole justification to release drug product batches, as contamination is not uniformly distributed in a system and any given sample may not be representative.” Passing tests are not proof of a controlled process.
Recurrence across sites escalated it to management
Similar observations at a second facility moved the finding out of the quality unit and into the executive suite. FDA’s language is explicit: repeated failures at multiple sites “demonstrate that management oversight and control over the manufacture of drugs is inadequate.”
The pattern worth carrying forward
There is an instinct, when responding to a 483, to demonstrate that you were not idle — to show the inspector that this was already on your radar and actions were already under way. That instinct is correct when the actions worked. When they didn’t, the same list becomes a documented record of a CAPA system that cannot detect its own ineffectiveness.
A repeat observation is a fundamentally different finding from a first-time one, and it has to be answered differently. The question is no longer “what will you do about the contamination?” It is “why should we believe this attempt will succeed when the last three didn’t?” A response that doesn’t answer the second question hasn’t engaged with the citation.
- Can you state, in writing, why the earlier CAPA failed? If you cannot name the failure mode — wrong root cause, inadequate scope, no effectiveness check, unenforceable in practice — do not cite the CAPA. You are handing over evidence without an explanation.
- Did the earlier CAPA close with an effectiveness check capable of detecting recurrence? A CAPA closed on completion of training records, rather than on evidence the problem stopped, was never a CAPA. It was a task list.
- Does the new action differ in kind, or only in degree? More training, stricter procedures, and increased monitoring are the same intervention at higher intensity. If the original failure was in design, only a design change is responsive.
The firm here did several things right. It stopped production voluntarily, it committed to effectiveness verification before restart, and it did not dispute the observations. None of that compensated for the missing analysis of its own remediation history.
If an observation has been made before, the prior CAPA is going to be discussed — by you in the response, or by FDA in the warning letter. It is substantially better that it is you.
Veritas Quality Consultants works with pharmaceutical, medical device, and biologics manufacturers on Form 483 responses, root cause analysis, and CAPA development — built to FDA expectations inside the 15-day window.
Request a consultation